PubMed:2533791 JSONTXT

{"project":"bc5cdr-valid-experiment","denotations":[{"id":"T1","span":{"begin":55,"end":85},"obj":"Disease"},{"id":"T2","span":{"begin":163,"end":193},"obj":"Disease"},{"id":"T3","span":{"begin":333,"end":360},"obj":"Chemical"},{"id":"T4","span":{"begin":362,"end":367},"obj":"Chemical"},{"id":"T5","span":{"begin":373,"end":394},"obj":"Chemical"},{"id":"T6","span":{"begin":396,"end":401},"obj":"Chemical"},{"id":"T7","span":{"begin":470,"end":481},"obj":"Disease"},{"id":"T8","span":{"begin":553,"end":572},"obj":"Chemical"},{"id":"T9","span":{"begin":789,"end":794},"obj":"Chemical"},{"id":"T10","span":{"begin":839,"end":844},"obj":"Chemical"},{"id":"T11","span":{"begin":862,"end":867},"obj":"Chemical"},{"id":"T12","span":{"begin":896,"end":901},"obj":"Chemical"}],"text":"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.\nIn Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985. This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers. These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine. We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987. 93.4% pregnant women had the chance to be examined for HBsAg, and the positive rate was 1.4 to 1.5%. The HBeAg positive rate in HBsAg positive was 23 to 26%. The HBsAg positive rate in neonates and in infants before two months were 3% and 2% respectively. Some problems may arise, because 27 to 30% of infants need the fourth vaccination in some restricted areas."}

{"project":"bc5cdr-valid-deepseek-nr-ng-experiment","denotations":[{"id":"T1","span":{"begin":68,"end":85},"obj":"Disease"},{"id":"T2","span":{"begin":195,"end":198},"obj":"Disease"},{"id":"T3","span":{"begin":333,"end":360},"obj":"Chemical"},{"id":"T4","span":{"begin":362,"end":367},"obj":"Chemical"},{"id":"T5","span":{"begin":373,"end":394},"obj":"Chemical"},{"id":"T6","span":{"begin":396,"end":401},"obj":"Chemical"},{"id":"T7","span":{"begin":470,"end":497},"obj":"Chemical"},{"id":"T8","span":{"begin":499,"end":503},"obj":"Chemical"},{"id":"T9","span":{"begin":538,"end":572},"obj":"Chemical"},{"id":"T10","span":{"begin":789,"end":794},"obj":"Chemical"},{"id":"T11","span":{"begin":839,"end":844},"obj":"Chemical"}],"text":"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.\nIn Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985. This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers. These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine. We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987. 93.4% pregnant women had the chance to be examined for HBsAg, and the positive rate was 1.4 to 1.5%. The HBeAg positive rate in HBsAg positive was 23 to 26%. The HBsAg positive rate in neonates and in infants before two months were 3% and 2% respectively. Some problems may arise, because 27 to 30% of infants need the fourth vaccination in some restricted areas."}

{"project":"bc5cdr-valid-deepseek-nr-g-experiment","denotations":[{"id":"T1","span":{"begin":68,"end":85},"obj":"Disease"},{"id":"T2","span":{"begin":176,"end":193},"obj":"Disease"},{"id":"T3","span":{"begin":195,"end":198},"obj":"Disease"},{"id":"T4","span":{"begin":333,"end":360},"obj":"Disease"},{"id":"T5","span":{"begin":362,"end":367},"obj":"Disease"},{"id":"T6","span":{"begin":373,"end":394},"obj":"Disease"},{"id":"T7","span":{"begin":396,"end":401},"obj":"Disease"},{"id":"T8","span":{"begin":470,"end":497},"obj":"Chemical"},{"id":"T9","span":{"begin":499,"end":503},"obj":"Chemical"},{"id":"T10","span":{"begin":538,"end":572},"obj":"Chemical"},{"id":"T11","span":{"begin":789,"end":794},"obj":"Disease"},{"id":"T12","span":{"begin":839,"end":844},"obj":"Disease"}],"text":"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.\nIn Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985. This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers. These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine. We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987. 93.4% pregnant women had the chance to be examined for HBsAg, and the positive rate was 1.4 to 1.5%. The HBeAg positive rate in HBsAg positive was 23 to 26%. The HBsAg positive rate in neonates and in infants before two months were 3% and 2% respectively. Some problems may arise, because 27 to 30% of infants need the fourth vaccination in some restricted areas."}

{"project":"bc5cdr-valid-gpt-r-ng-experiment","denotations":[{"id":"T1","span":{"begin":55,"end":85},"obj":"Disease"},{"id":"T2","span":{"begin":163,"end":193},"obj":"Disease"},{"id":"T3","span":{"begin":333,"end":360},"obj":"Chemical"},{"id":"T4","span":{"begin":362,"end":367},"obj":"Chemical"},{"id":"T5","span":{"begin":373,"end":394},"obj":"Chemical"},{"id":"T6","span":{"begin":396,"end":401},"obj":"Chemical"},{"id":"T7","span":{"begin":470,"end":497},"obj":"Chemical"},{"id":"T8","span":{"begin":499,"end":503},"obj":"Chemical"},{"id":"T9","span":{"begin":538,"end":572},"obj":"Chemical"},{"id":"T10","span":{"begin":789,"end":794},"obj":"Chemical"},{"id":"T11","span":{"begin":839,"end":844},"obj":"Chemical"},{"id":"T12","span":{"begin":862,"end":867},"obj":"Chemical"}],"text":"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.\nIn Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985. This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers. These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine. We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987. 93.4% pregnant women had the chance to be examined for HBsAg, and the positive rate was 1.4 to 1.5%. The HBeAg positive rate in HBsAg positive was 23 to 26%. The HBsAg positive rate in neonates and in infants before two months were 3% and 2% respectively. Some problems may arise, because 27 to 30% of infants need the fourth vaccination in some restricted areas."}

{"project":"bc5cdr-valid-gpt-r-g-experiment","denotations":[{"id":"T1","span":{"begin":68,"end":85},"obj":"Disease"},{"id":"T2","span":{"begin":176,"end":193},"obj":"Disease"},{"id":"T3","span":{"begin":195,"end":198},"obj":"Disease"}],"text":"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.\nIn Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985. This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers. These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine. We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987. 93.4% pregnant women had the chance to be examined for HBsAg, and the positive rate was 1.4 to 1.5%. The HBeAg positive rate in HBsAg positive was 23 to 26%. The HBsAg positive rate in neonates and in infants before two months were 3% and 2% respectively. Some problems may arise, because 27 to 30% of infants need the fourth vaccination in some restricted areas."}

{"project":"bc5cdr-valid-gpt-r-m30","denotations":[{"id":"T1","span":{"begin":55,"end":85},"obj":"Disease"},{"id":"T2","span":{"begin":163,"end":193},"obj":"Disease"}],"text":"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.\nIn Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985. This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers. These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine. We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987. 93.4% pregnant women had the chance to be examined for HBsAg, and the positive rate was 1.4 to 1.5%. The HBeAg positive rate in HBsAg positive was 23 to 26%. The HBsAg positive rate in neonates and in infants before two months were 3% and 2% respectively. Some problems may arise, because 27 to 30% of infants need the fourth vaccination in some restricted areas."}

{"project":"bc5cdr-valid-gpt-r-m20","denotations":[{"id":"T1","span":{"begin":55,"end":64},"obj":"Disease"},{"id":"T2","span":{"begin":68,"end":79},"obj":"Disease"},{"id":"T3","span":{"begin":163,"end":172},"obj":"Disease"},{"id":"T4","span":{"begin":176,"end":187},"obj":"Disease"},{"id":"T5","span":{"begin":333,"end":344},"obj":"Disease"},{"id":"T6","span":{"begin":470,"end":481},"obj":"Disease"},{"id":"T7","span":{"begin":553,"end":564},"obj":"Disease"}],"text":"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.\nIn Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985. This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers. These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine. We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987. 93.4% pregnant women had the chance to be examined for HBsAg, and the positive rate was 1.4 to 1.5%. The HBeAg positive rate in HBsAg positive was 23 to 26%. The HBsAg positive rate in neonates and in infants before two months were 3% and 2% respectively. Some problems may arise, because 27 to 30% of infants need the fourth vaccination in some restricted areas."}